LSP1 promotes the progression of acute myelogenous leukemia by regulating KSR/ERK signaling pathway and cell migration

References

• Heuser M, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712. doi:10.1016/j.annonc.2020.02.018
   PubMed Web of Science ®Google Scholar
• Wojcicki AV, et al. Metabolomics in acute myeloid leukemia. Mol Genet Metab. 2020;130(4):230–238. doi:10.1016/j.ymgme.2020.05.005
   PubMed Web of Science ®Google Scholar
• Sung PJ, Luger SM. Minimal residual disease in acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(1):1. doi:10.1007/s11864-017-0447-3
   PubMed Web of Science ®Google Scholar
• Zeng AGX, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212–1223. doi:10.1038/s41591-022-01819-x
   PubMed Web of Science ®Google Scholar
• Lu J, et al. Eukaryotic initiation factor-2, gamma subunit, suppresses proliferation and regulates the cell cycle via the MAPK/ERK signaling pathway in acute myeloid leukemia. J Cancer Res Clin Oncol. 2021;147(11):3157–3168. doi:10.1007/s00432-021-03712-5
   PubMed Web of Science ®Google Scholar
• McMahon CM, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050–1063. doi:10.1158/2159-8290.CD-18-1453
   PubMed Web of Science ®Google Scholar
• Schmalbrock LK, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137(22):3093–3104. doi:10.1182/blood.2020007626
   PubMed Web of Science ®Google Scholar
• Duarte D, et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell. 2018;22(1):64–77 e6. doi:10.1016/j.stem.2017.11.006
   PubMed Web of Science ®Google Scholar
• Boyd AL, et al. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J Exp Med. 2014;211(10):1925–1935. doi:10.1084/jem.20140131
   PubMed Web of Science ®Google Scholar
• Mead AJ, et al. Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation. J Exp Med. 2017;214(7):2005–2021. doi:10.1084/jem.20161418
   PubMed Web of Science ®Google Scholar
• Johansen S, et al. The possible importance of beta3 integrins for leukemogenesis and chemoresistance in acute myeloid leukemia. Int J Mol Sci. 2018;19(1. doi:10.3390/ijms19010251
   Web of Science ®Google Scholar
• Pelletier SD, et al. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice. Blood. 2004;104(7):2163–2171. doi:10.1182/blood-2003-09-3033
   PubMed Web of Science ®Google Scholar
• Su L, Hu Z, Yang YG. Role of CXCR4 in the progression and therapy of acute leukaemia. Cell Prolif. 2021;54(7):e13076. doi:10.1111/cpr.13076
   PubMed Web of Science ®Google Scholar
• Jongstra-Bilen J, Jongstra J. Leukocyte-specific protein 1 (LSP1): a regulator of leukocyte emigration in inflammation. Immunol Res. 2006;35(1-2):65–74. doi:10.1385/IR:35:1:65
   PubMed Web of Science ®Google Scholar
• Le NPK, et al. Deficiency of leukocyte-specific protein 1 (LSP1) alleviates asthmatic inflammation in a mouse model. Respir Res. 2022;23(1):165. doi:10.1186/s12931-022-02078-7
   PubMed Web of Science ®Google Scholar
• Scharinger K, et al. LSP1-myosin1e bimolecular complex regulates focal adhesion dynamics and cell migration. FASEB J. 2021;35(2):e21268. doi:10.1096/fj.202000740RR
   PubMed Web of Science ®Google Scholar
• Le NP, et al. Leukocyte-specific protein 1 regulates neutrophil recruitment in acute lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2015;309(9):L995–1008. doi:10.1152/ajplung.00068.2014
   PubMed Web of Science ®Google Scholar
• Hossain M, et al. Endothelial LSP1 modulates extravascular neutrophil chemotaxis by regulating nonhematopoietic vascular PECAM-1 expression. J Immunol. 2015;195(5):2408–2416. doi:10.4049/jimmunol.1402225
   PubMed Web of Science ®Google Scholar
• Cong P, et al. MiR-920 and LSP1 co-regulate the growth and migration of glioblastoma cells by modulation of JAK2/STAT5 pathway. J Bioenerg Biomembr. 2020;52(5):311–320. doi:10.1007/s10863-020-09848-2
   PubMed Web of Science ®Google Scholar
• Meyer WH, Howard TH. Actin polymerization and its relationship to locomotion and chemokinetic response in maturing human promyelocytic leukemia cells. Blood. 1987;70(2):363–367. doi:10.1182/blood.V70.2.363.363
   PubMed Web of Science ®Google Scholar
• Li Y, et al. LSP1 modulates the locomotion of monocyte-differentiated U937 cells. Blood. 2000;96(3):1100–1105. doi:10.1182/blood.V96.3.1100
   PubMed Web of Science ®Google Scholar
• Hossain M, et al. ICAM-1-mediated leukocyte adhesion is critical for the activation of endothelial LSP1. Am J Physiol Cell Physiol. 2013;304(9):C895–C904. doi:10.1152/ajpcell.00297.2012
   PubMed Web of Science ®Google Scholar
• Harrison RE, Sikorski BA, Jongstra J. Leukocyte-specific protein 1 targets the ERK/MAP kinase scaffold protein KSR and MEK1 and ERK2 to the actin cytoskeleton. J Cell Sci. 2004;117(Pt 10):2151–2157. doi:10.1242/jcs.00955
   PubMed Web of Science ®Google Scholar
• Wu Y, et al. MAPKAPK2-mediated LSP1 phosphorylation and FMLP-induced neutrophil polarization. Biochem Biophys Res Commun. 2007;358(1):170–175. doi:10.1016/j.bbrc.2007.04.104
   PubMed Web of Science ®Google Scholar
• Li Y, Guerrero A, Howard TH. The actin-binding protein, lymphocyte-specific protein 1, is expressed in human leukocytes and human myeloid and lymphoid cell lines. J Immunol. 1995;155(7):3563–3569. doi:10.4049/jimmunol.155.7.3563
   PubMed Web of Science ®Google Scholar
• Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577–590. doi:10.1038/s41571-021-00509-w
   PubMed Web of Science ®Google Scholar
• Hosen N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104(26):11008–11013. doi:10.1073/pnas.0704271104
   PubMed Web of Science ®Google Scholar
• Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33. doi:10.1016/j.cell.2017.06.009
   PubMed Web of Science ®Google Scholar
• Ni F, et al. Ptpn21 controls hematopoietic stem cell homeostasis and biomechanics. Cell Stem Cell. 2019;24(4):608–620 e6. doi:10.1016/j.stem.2019.02.009
   PubMed Web of Science ®Google Scholar
• Li M, et al. METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4. Leukemia. 2022;36(11):2586–2595. doi:10.1038/s41375-022-01696-w
   PubMed Web of Science ®Google Scholar
• Salvestrini V, et al. Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood. 2012;119(1):217–226. doi:10.1182/blood-2011-07-370775
   PubMed Web of Science ®Google Scholar
• Wagner S, et al. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Adv. 2019;3(8):1330–1346. doi:10.1182/bloodadvances.2018030726
   PubMed Web of Science ®Google Scholar
• Zhao X, Li Y, Wu H. A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes. Int J Mol Med. 2018;42(3):1495–1507.
   PubMed Web of Science ®Google Scholar
• Moore AR, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533–552. doi:10.1038/s41573-020-0068-6
   PubMed Web of Science ®Google Scholar